Healthcare Triangle, Inc. acquires SecureKloud Technologies Ltd. (2026)

Deal facts

Buyer: Healthcare Triangle, Inc.
Target: SecureKloud Technologies Ltd.
Deal value: Not disclosed
Announced: 26 June 2026
Status: Firm intention
Sector: Healthcare
Country: India
Consideration: shares, earn-out

Sources

What we know

Healthcare Triangle, Inc. has agreed to acquire SecureKloud Technologies Ltd. in a strategic acquisition valued at an undisclosed sum. The transaction consideration will comprise a mix of shares and an earn-out arrangement. Healthcare Triangle, a United States-based entity, is purchasing the Indian target firm which operates within the healthcare sector. The deal was announced on 26 June 2026 and currently stands at the firm intention stage.

No completion date has been confirmed as the transaction remains pending finalisation. The parties have not disclosed the specific financial terms or the exact valuation of the deal at this time. Regulatory approvals and other standard conditions precedent must be satisfied before the acquisition can proceed to completion. The management team of SecureKloud Technologies will continue to operate the business under the new ownership structure. The transaction is subject to regulatory approval.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

26 Jun 2026Firm intention
Healthcare Triangle, Inc. firm intention to acquire SecureKloud Technologies Ltd.
Item 1.01 Entry into a Material Definitive Agreement. Securities Exchange Agreement with SecureKloud Technologies Ltd. On June 24, 2026, Healthcare Triangle, Inc. (the “Company”) entered into a Securities Exchange Agreement (the “Securities Exchange Agreement”) with SecureKloud Technologies Ltd., an Indian private limited company (“SecureKloud”). In consideration for the acquisition of substantial
Source

OpinionExit Mode editorial

We see a clear signal in the announcement that Healthcare Triangle, Inc. intends to acquire SecureKloud Technologies Ltd. This strategic move, confirmed on 26 June 2026, crosses the Atlantic from the US to India within the healthcare sector. The deal structure relies entirely on shares and an earn-out arrangement, with no cash value disclosed at this stage. For the SME founder reading this, the absence of an upfront cash figure is significant. It shifts the risk profile entirely onto the future performance of the combined entity.

The use of an earn-out mechanism in a cross-border transaction introduces specific commercial complexities. The seller's ultimate payout depends on hitting targets set by the buyer after the deal closes. In a sector as regulated as healthcare, these targets often hinge on regulatory clearance or the successful integration of disparate compliance frameworks. A change-of-control covenant could also trigger if the buyer fails to secure necessary approvals from bodies like the CMA or equivalent Indian authorities. The reliance on shares further ties the founder's wealth to the market performance of the acquiring company, a factor outside their direct control once the transaction completes.

This structure suggests the buyer values the target's technology or talent but wishes to mitigate immediate valuation risk. It is a common tactic when dealing with international targets where due diligence on local market conditions or regulatory hurdles remains uncertain. The firm intention status means the parties are serious, yet the lack of a fixed price indicates that the final value is still being negotiated based on future milestones. We view this as a pragmatic approach for a buyer entering a new geography, but it demands that the target founder fully understands the triggers for their potential payout.

You must request a written schedule of the earn-out metrics and the specific governance rights you will retain during the earn-out period before signing any term sheet. Do not accept vague language regarding how performance is measured or how disputes over targets will be resolved. Ensure the agreement specifies what happens if the buyer makes strategic decisions that make hitting those targets impossible.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Healthcare Triangle, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

13 October 2026CompletedHealthcare

Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…

Buyer: Alaunos Therapeutics, Inc.
Target: Velaris Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

11 October 2026Firm intentionHealthcare

STERIS Corporation to acquire Xodus Medical, Inc.

STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…

Buyer: STERIS Corporation
Target: Xodus Medical, Inc.
Deal value: USD 2,100,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

9 October 2026CompletedHealthcare

Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC

Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…

Buyer: Hepion Pharmaceuticals, Inc.
Target: Gravitas Life Sciences, LLC
Deal value: USD 4,250,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history